NO20023831L - Pyrrol substituert 2-indolinonproteinkinaseinhibitorer - Google Patents
Pyrrol substituert 2-indolinonproteinkinaseinhibitorerInfo
- Publication number
- NO20023831L NO20023831L NO20023831A NO20023831A NO20023831L NO 20023831 L NO20023831 L NO 20023831L NO 20023831 A NO20023831 A NO 20023831A NO 20023831 A NO20023831 A NO 20023831A NO 20023831 L NO20023831 L NO 20023831L
- Authority
- NO
- Norway
- Prior art keywords
- protein kinase
- pyrrole
- substitutes
- kinase inhibitors
- indolinone protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18271000P | 2000-02-15 | 2000-02-15 | |
US21642200P | 2000-07-06 | 2000-07-06 | |
US24353200P | 2000-10-27 | 2000-10-27 | |
PCT/US2001/004813 WO2001060814A2 (en) | 2000-02-15 | 2001-02-15 | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20023831D0 NO20023831D0 (no) | 2002-08-13 |
NO20023831L true NO20023831L (no) | 2002-10-15 |
NO325532B1 NO325532B1 (no) | 2008-06-09 |
Family
ID=27391578
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20023831A NO325532B1 (no) | 2000-02-15 | 2002-08-13 | Pyrrolsubstituerte 2-indolinoner, farmasoytisk preparat omfattende slike, fremgangsmate for a modulere den katalytiske aktiviteten til en proteinkinase in vitro basert pa bruk av slike forbindelser, samt anvendelse av slike forbindelser til fremstilling av medikamenter for behandling av sykdommer. |
NO2008019C NO2008019I2 (no) | 2000-02-15 | 2008-12-08 | Sunitinib |
NO2010002C NO2010002I2 (no) | 2000-02-15 | 2010-02-09 | Toceranibfosfat. |
NO2019005C NO2019005I1 (no) | 2000-02-15 | 2019-02-05 | N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-1,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid (sunitinib), samt farmasøytisk akseptable salter |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2008019C NO2008019I2 (no) | 2000-02-15 | 2008-12-08 | Sunitinib |
NO2010002C NO2010002I2 (no) | 2000-02-15 | 2010-02-09 | Toceranibfosfat. |
NO2019005C NO2019005I1 (no) | 2000-02-15 | 2019-02-05 | N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-1,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid (sunitinib), samt farmasøytisk akseptable salter |
Country Status (43)
Families Citing this family (331)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569868B2 (en) | 1998-04-16 | 2003-05-27 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
JP4865129B2 (ja) | 1999-01-13 | 2012-02-01 | ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク | タンパク質キナーゼ阻害剤を設計するための新規の方法 |
ME00415B (me) * | 2000-02-15 | 2011-10-10 | Pharmacia & Upjohn Co Llc | Pirol supstituisani 2-indol protein kinazni inhibitori |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
TWI270545B (en) | 2000-05-24 | 2007-01-11 | Sugen Inc | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
AU2001268154A1 (en) | 2000-06-02 | 2001-12-17 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
WO2002002551A1 (en) * | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
DE60126997T2 (de) | 2000-10-20 | 2007-10-25 | Eisai R&D Management Co., Ltd. | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen |
JP2004518669A (ja) * | 2000-12-20 | 2004-06-24 | スージェン・インコーポレーテッド | 4−アリール置換インドリノン |
AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
EP1247809A3 (en) * | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
AU2002303892A1 (en) | 2001-05-30 | 2002-12-09 | Jingrong Cui | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
CA2452361A1 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
AR038957A1 (es) * | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
EA006445B9 (ru) * | 2001-08-15 | 2017-02-28 | Фармация Энд Апджон Компани | Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции |
BR0212435A (pt) | 2001-09-10 | 2004-08-17 | Sugen Inc | Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase |
WO2003031438A1 (en) * | 2001-10-10 | 2003-04-17 | Sugen, Inc. | 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors |
US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
EP1444204A4 (en) * | 2001-10-22 | 2009-11-04 | Univ New York State Res Found | INHIBITORS OF PROTEIN KINASES AND PROTEINS PHOSPHATASES, METHODS OF IDENTIFICATION AND METHODS OF USE THEREOF |
TWI259081B (en) * | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
US20030080191A1 (en) * | 2001-10-26 | 2003-05-01 | Allen Lubow | Method and apparatus for applying bar code information to products during production |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
AU2002366245A1 (en) * | 2001-12-17 | 2003-06-30 | International Barcode Corporation | Double-sided bar code doubling as a single bar code |
US20050131733A1 (en) * | 2001-12-17 | 2005-06-16 | Allen Lubow | Sealable individual bar coded packets |
EP1458713B1 (en) | 2001-12-27 | 2005-08-24 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
CA2475455A1 (en) * | 2002-02-15 | 2003-08-28 | Pharmacia & Upjohn Company | Process for preparing indolinone derivatives |
WO2003097854A2 (en) * | 2002-05-17 | 2003-11-27 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
ITMI20021620A1 (it) * | 2002-07-23 | 2004-01-23 | Novuspharma Spa | Composto ad ativita' antitumorale |
WO2004016211A2 (en) * | 2002-08-08 | 2004-02-26 | Vanderbilt University | Pi3k antagonists as radiosensitizers |
AU2003259713A1 (en) * | 2002-08-09 | 2004-02-25 | Theravance, Inc. | Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same |
US20040121407A1 (en) * | 2002-09-06 | 2004-06-24 | Elixir Pharmaceuticals, Inc. | Regulation of the growth hormone/IGF-1 axis |
HN2003000272A (es) * | 2002-09-10 | 2008-07-29 | Pharmacia Italia Spa | Formulaciones que comprenden un compuesto de indolinona |
AR042042A1 (es) * | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
AU2003302665B2 (en) * | 2002-11-15 | 2009-12-24 | Symphony Evolution, Inc. | Kinase modulators |
US20040209937A1 (en) * | 2003-02-24 | 2004-10-21 | Sugen, Inc. | Treatment of excessive osteolysis with indolinone compounds |
US7452913B2 (en) * | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
BRPI0407827B8 (pt) | 2003-02-26 | 2021-05-25 | Sugen Inc | compostos de aminoeteroarila como inibidores de proteína cinase e respectivos usos |
US20040266843A1 (en) * | 2003-03-07 | 2004-12-30 | Sugen, Inc. | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) |
US7157577B2 (en) * | 2003-03-07 | 2007-01-02 | Sugen Inc. | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors |
JPWO2004080462A1 (ja) * | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | c−Kitキナーゼ阻害剤 |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
DE10334582A1 (de) * | 2003-07-28 | 2005-02-24 | Basf Ag | Verfahren zur Herstellung von Maleinsäureanhydrid |
WO2005023765A1 (en) * | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
KR20080007520A (ko) * | 2003-10-02 | 2008-01-21 | 파마시아 앤드 업존 캄파니 엘엘씨 | 피롤-치환된 인돌리논 화합물의 염 및 다형체 |
SI1680140T1 (sl) * | 2003-10-16 | 2011-08-31 | Imclone Llc | Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi |
JP4890255B2 (ja) | 2003-11-07 | 2012-03-07 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩 |
WO2005044788A1 (ja) | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
EP1686987A4 (en) * | 2003-11-26 | 2009-02-25 | Scripps Research Inst | ADVANCED PROTEIN KINASE HEMMER ON INDOLINO BASIS |
EP1699477A2 (en) * | 2003-12-11 | 2006-09-13 | Theravance, Inc. | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
US20050152943A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
WO2005118543A1 (ja) * | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | キナーゼ阻害薬およびその用途 |
WO2006002422A2 (en) | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
SE0401790D0 (sv) * | 2004-07-07 | 2004-07-07 | Forskarpatent I Syd Ab | Tamoxifen response in pre- and postmenopausal breast cancer patients |
US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
PL1786785T3 (pl) * | 2004-08-26 | 2010-08-31 | Pfizer | Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe |
KR20070053205A (ko) | 2004-09-17 | 2007-05-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 의약 조성물 |
CN100432071C (zh) * | 2004-11-05 | 2008-11-12 | 中国科学院上海药物研究所 | 取代1h-吲哚-2-酮类化合物及其制备方法和用途 |
GT200500321A (es) | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
BRPI0607579A2 (pt) * | 2005-03-23 | 2009-09-15 | Pfizer Prod Inc | uso de anticorpo anti-ctla4 e indolinona para a preparação de medicamentos para o tratamento de cáncer |
KR100990027B1 (ko) | 2005-04-26 | 2010-10-26 | 화이자 인코포레이티드 | P-카드헤린 항체 |
RU2007141654A (ru) * | 2005-05-12 | 2009-05-20 | Пфайзер Инк. (US) | Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат |
CN102304086B (zh) | 2005-05-18 | 2013-12-04 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
MX2007014782A (es) | 2005-05-23 | 2008-02-19 | Novartis Ag | Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona. |
JP2008542294A (ja) * | 2005-05-26 | 2008-11-27 | ザ スクリプス リサーチ インスティテュート | 向上したインドリノン系プロテインキナーゼ阻害剤 |
US20100105031A1 (en) * | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
RS54393B1 (en) | 2005-09-07 | 2016-04-28 | Amgen Fremont Inc. | HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR |
ES2328407T3 (es) * | 2005-09-19 | 2009-11-12 | Pfizer Products Incorporated | Formas salinas solidas de una 2-indolinona sustituida con pirrol. |
US20090053236A1 (en) * | 2005-11-07 | 2009-02-26 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
CN101389331A (zh) * | 2005-12-29 | 2009-03-18 | 斯克里普斯研究学院 | 基于吲哚满酮的氨基酸衍生物的蛋白激酶抑制剂 |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CN101007801A (zh) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | 吡咯取代的2-二氢吲哚酮衍生物、其制法与医药上的用途 |
TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
WO2007124288A1 (en) | 2006-04-19 | 2007-11-01 | Novartis Ag | Indazole compounds and methods for inhibition of cdc7 |
JP4383525B2 (ja) | 2006-05-09 | 2009-12-16 | ファイザー・プロダクツ・インク | シクロアルキルアミノ酸誘導体およびその医薬組成物 |
RU2448708C3 (ru) * | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
WO2008001956A1 (fr) * | 2006-06-29 | 2008-01-03 | Eisai R & D Management Co., Ltd. | Agent thérapeutique contre la fibrose hépatique |
AU2007272330A1 (en) | 2006-07-13 | 2008-01-17 | Zymogenetics, Inc. | Interleukin 21 and tyrosine kinase inhibitor combination therapy |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
CL2007002261A1 (es) | 2006-08-04 | 2008-05-02 | Takeda Pharmaceutical | Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer. |
PL2057156T3 (pl) | 2006-08-23 | 2017-08-31 | Kudos Pharmaceuticals Limited | Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR |
WO2008026748A1 (fr) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
ES2565683T3 (es) | 2006-09-15 | 2016-04-06 | Xcovery, Inc. | Compuestos inhibidores de quinasa |
WO2008056634A1 (fr) * | 2006-11-06 | 2008-05-15 | Theravalues Corporation | Nouveau dérivé d'hydroxyindole |
MY146474A (en) | 2006-11-06 | 2012-08-15 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
WO2008067756A1 (fr) | 2006-12-04 | 2008-06-12 | Jiangsu Simcere Pharmaceutical R & D Co., Ltd. | Dérivés de 3-pyrrolo-cyclohexylène-2-dihydro-indolinone et utilisations de ceux-ci |
CN101600694A (zh) | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | 未分化型胃癌治疗用组合物 |
JP4523073B2 (ja) | 2007-02-06 | 2010-08-11 | ファイザー・インク | 癌を治療するためのHSP−90阻害剤としての2−アミノ−5,7−ジヒドロ−6H−ピロロ[3,4−d]ピリミジン誘導体 |
JPWO2008114819A1 (ja) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
US20090042906A1 (en) * | 2007-04-26 | 2009-02-12 | Massachusetts Institute Of Technology | Methods for treating cancers associated with constitutive egfr signaling |
WO2008138184A1 (fr) | 2007-05-14 | 2008-11-20 | Shanghai Hengrui Pharmaceutical Co.Ltd. | Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases |
WO2008145398A1 (en) * | 2007-06-01 | 2008-12-04 | Pfizer Italia S.R.L. | 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors |
CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
US8324395B2 (en) | 2007-08-23 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US20090062368A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched sunitinib |
HUE030774T2 (hu) * | 2007-09-06 | 2017-05-29 | Boston Biomedical Inc | Kinázinhibitorokból álló készítmények és felhasználásuk a rák és a kinázokhoz kapcsolódó más betegségek kezelésére |
KR101494734B1 (ko) | 2007-10-11 | 2015-02-26 | 아스트라제네카 아베 | 단백질 키나제 b 억제제로서 피롤로[2,3-d]피리미딘 유도체 |
JP5638244B2 (ja) | 2007-11-09 | 2014-12-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
WO2009067686A2 (en) * | 2007-11-21 | 2009-05-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof |
CA2709083A1 (en) * | 2007-12-12 | 2009-06-18 | Medichem S.A. | Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
DK2222675T3 (da) | 2007-12-19 | 2013-11-04 | Genentech Inc | 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse |
EP2240475B1 (en) | 2007-12-20 | 2013-09-25 | Novartis AG | Thiazole derivatives used as pi 3 kinase inhibitors |
JP5710269B2 (ja) | 2007-12-21 | 2015-04-30 | ジェネンテック, インコーポレイテッド | アザインドリジン類と使用方法 |
JP5399926B2 (ja) * | 2008-01-29 | 2014-01-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管阻害物質とタキサンとの併用 |
EP2113248A1 (en) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide |
EP2090306A1 (en) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
US20100310668A1 (en) * | 2008-02-13 | 2010-12-09 | Ratiopharm Gmbh | Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide |
CN101255154B (zh) * | 2008-02-18 | 2011-09-07 | 靳广毅 | 一种取代的2-吲哚啉酮衍生物和制备方法及其应用 |
US20110112164A1 (en) * | 2008-02-21 | 2011-05-12 | Generics (Uk) Limited | Novel polymorphs and processes for their preparation |
EP2098521A1 (en) * | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation |
ES2391501T3 (es) * | 2008-03-31 | 2012-11-27 | Teva Pharmaceutical Industries Ltd. | Procedimientos para preparar sunitinib y sales del mismo |
WO2009128083A1 (en) * | 2008-04-16 | 2009-10-22 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
US8158656B2 (en) * | 2008-05-16 | 2012-04-17 | Shenzhen Chipscreen Biosciences Ltd. | 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
CN102066362B (zh) * | 2008-05-23 | 2014-07-30 | 上海医药工业研究院 | 二氢吲哚酮衍生物 |
WO2009154697A2 (en) | 2008-05-28 | 2009-12-23 | Massachusetts Institute Of Technology | Disc-1 pathway activators in the control of neurogenesis |
SI2313371T1 (sl) * | 2008-06-13 | 2013-02-28 | Medichem, S.A. | Postopek za pripravo soli 3-pirol substituirane 2-indolinonske jabolčne kisline |
WO2009157011A1 (en) * | 2008-06-23 | 2009-12-30 | Natco Pharma Limited | Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt |
EP2138167A1 (en) * | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
WO2009156837A2 (en) * | 2008-06-26 | 2009-12-30 | Medichem, S.A. | Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt |
DE102008031038A1 (de) | 2008-06-30 | 2009-12-31 | Alexander Priv.-Doz. Dr. Dömling | Sutent zur Anwendung in der Organtransplantation |
MX2011000150A (es) * | 2008-06-30 | 2011-04-05 | Cylene Pharmaceuticals Inc | Compuestos de oxoindol. |
KR20110036101A (ko) | 2008-06-30 | 2011-04-06 | 안지오블라스트 시스템스 인코퍼레이티드 | 조합된 치료를 사용한 안과질환 및 과도한 혈관신생의 치료 |
AU2009265360A1 (en) * | 2008-07-02 | 2010-01-07 | Generics [Uk] Limited | Preparation of 3-pyrrole substituted 2-indolinone derivatives |
WO2010004339A1 (en) * | 2008-07-10 | 2010-01-14 | Generics [Uk] Limited | Processes for the preparation of crystalline forms of sunitinib malate |
EP2342195B1 (en) | 2008-07-24 | 2014-09-10 | Medichem, S.A. | Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt |
CA2731605A1 (en) * | 2008-07-24 | 2010-01-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib and salts thereof and their polymorphs |
WO2010017541A2 (en) * | 2008-08-08 | 2010-02-11 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
WO2010027828A2 (en) * | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
PL2350129T3 (pl) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Kompozycje antagonistów PD-1 i sposoby stosowania |
US20110263670A1 (en) * | 2008-08-25 | 2011-10-27 | Vinayak Gore | Novel polymorphs of sunitinib and processes for their preparation |
WO2010023473A2 (en) * | 2008-08-25 | 2010-03-04 | Generics [Uk] Limited | Novel crystalline form and processes for its preparation |
WO2010026388A1 (en) * | 2008-09-05 | 2010-03-11 | Imperial Innovations Limited | Isatin derivatives for use as in vivo imaging agents |
JP5778577B2 (ja) | 2008-09-19 | 2015-09-16 | メディミューン,エルエルシー | Dll4に対する抗体およびその使用 |
AR073807A1 (es) * | 2008-10-10 | 2010-12-01 | Medichem Sa | Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria. |
EP2181991A1 (en) * | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
US20100222371A1 (en) * | 2008-11-20 | 2010-09-02 | Children's Medical Center Corporation | Prevention of surgical adhesions |
JP5579619B2 (ja) | 2008-12-01 | 2014-08-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
TW201028410A (en) | 2008-12-22 | 2010-08-01 | Astrazeneca Ab | Chemical compounds 610 |
CA2748158A1 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
EP2373643A4 (en) | 2009-01-02 | 2013-08-07 | Hetero Research Foundation | NEW SUNITINIB MALATE POLYMORPHS |
KR20240011244A (ko) | 2009-01-16 | 2024-01-25 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
NZ594177A (en) | 2009-02-05 | 2014-02-28 | Immunogen Inc | Novel benzodiazepine derivatives |
EP2393814A1 (en) | 2009-02-09 | 2011-12-14 | SuperGen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
TW201035088A (en) | 2009-02-27 | 2010-10-01 | Supergen Inc | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
US9265764B2 (en) * | 2009-02-27 | 2016-02-23 | Massachusetts Institute Of Technology | Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders |
CA2755061A1 (en) | 2009-03-13 | 2010-09-16 | Cellzome Limited | Pyrimidine derivatives as mtor inhibitors |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
CA2758614A1 (en) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
US8530492B2 (en) | 2009-04-17 | 2013-09-10 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
EP2255792A1 (en) | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide |
US8211901B2 (en) | 2009-05-22 | 2012-07-03 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
EP2264027A1 (en) * | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
CN101906076B (zh) | 2009-06-04 | 2013-03-13 | 深圳微芯生物科技有限责任公司 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
WO2011004200A1 (en) | 2009-07-10 | 2011-01-13 | Generics [Uk] Limited | Novel pyrrole derivatives |
FR2948940B1 (fr) * | 2009-08-04 | 2011-07-22 | Servier Lab | Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2011029807A1 (en) | 2009-09-11 | 2011-03-17 | Cellzome Limited | Ortho substituted pyrimidine compounds as jak inhibitors |
AU2010296849A1 (en) | 2009-09-16 | 2012-05-03 | Ranbaxy Laboratories Limited | Salts of sunitinib |
TW201125867A (en) | 2009-10-20 | 2011-08-01 | Cellzome Ltd | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors |
EP2499133A2 (en) | 2009-11-12 | 2012-09-19 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form i of l-malic acid salt of sunitinib |
US8916716B2 (en) | 2009-11-19 | 2014-12-23 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form II of L-malic acid salt of sunitinib |
CA2778714C (en) | 2009-11-24 | 2018-02-27 | Medimmune Limited | Targeted binding agents against b7-h1 |
WO2011068233A1 (en) | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
WO2011095802A1 (en) | 2010-02-02 | 2011-08-11 | Generics [Uk] Limited | Hplc method for analyzing sunitinib |
WO2011100325A2 (en) * | 2010-02-09 | 2011-08-18 | Sicor Inc. | Polymorphs of sunitinib salts |
AU2011215900A1 (en) | 2010-02-10 | 2012-07-26 | Immunogen, Inc. | CD20 antibodies and uses thereof |
RU2012139182A (ru) | 2010-02-22 | 2014-03-27 | Ф. Хоффманн-Ля Рош Аг | ПИРИДО[3,2-d]ПИРИМИДИНЫ - ИНГИБИТОРЫ PI3К ДЕЛЬТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
WO2011104555A2 (en) | 2010-02-25 | 2011-09-01 | Generics [Uk] Limited | Novel process |
ES2535116T3 (es) | 2010-03-04 | 2015-05-05 | Cellzome Limited | Derivados de urea sustituida con morfolino como inhibidores de mtor |
AU2011222470A1 (en) | 2010-03-04 | 2012-09-27 | Ranbaxy Laboratories Limited | Process for the direct preparation of malic acid salt of sunitinib |
CN102858739A (zh) * | 2010-03-10 | 2013-01-02 | 斯索恩有限公司 | 酰胺化吡咯甲酸酯化合物的方法 |
AU2011228765A1 (en) | 2010-03-18 | 2012-10-11 | Ranbaxy Laboratories Limited | Process for the preparation of malic acid salt of sunitinib |
EP2550263A4 (en) | 2010-03-23 | 2013-07-24 | Univ Johns Hopkins | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE |
WO2011128699A2 (en) * | 2010-04-16 | 2011-10-20 | Generics [Uk] Limited | Novel process |
SG184989A1 (en) | 2010-04-30 | 2012-11-29 | Cellzome Ltd | Pyrazole compounds as jak inhibitors |
WO2011138565A1 (fr) | 2010-05-05 | 2011-11-10 | Biorebus | Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs |
EP2392324A1 (en) | 2010-06-01 | 2011-12-07 | Societe De Coordination De Recherches Therapeutiques | Rhenium complexes and their pharmaceutical use |
SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
EP2588105A1 (en) | 2010-07-01 | 2013-05-08 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
WO2012006503A1 (en) | 2010-07-09 | 2012-01-12 | Genentech, Inc. | Anti-neuropilin antibodies and methods of use |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
US9040545B2 (en) | 2010-08-20 | 2015-05-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors |
WO2012027716A1 (en) | 2010-08-27 | 2012-03-01 | Collabrx, Inc. | Method to treat melanoma in braf inhibitor-resistant subjects |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
EP2635568B1 (en) | 2010-11-01 | 2017-08-16 | Scinopharm (Kunshan) Biochemical Technology Co., Ltd. | Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles |
WO2012059941A1 (en) * | 2010-11-04 | 2012-05-10 | Ind-Swift Laboratories Limited | Process for preparation of sunitinib malate and salts thereof |
EP2638018A1 (en) | 2010-11-09 | 2013-09-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
EP2640384A1 (en) | 2010-11-18 | 2013-09-25 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
EP2640360A2 (en) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
AR083868A1 (es) | 2010-12-03 | 2013-03-27 | Lilly Co Eli | Compuestos de oxazol[5,4-b]piridin-5-ilo |
JP6009457B2 (ja) | 2010-12-23 | 2016-10-19 | ネクター セラピューティクス | ポリマー−デスエチルスニチニブコンジュゲート |
JP6002149B2 (ja) | 2010-12-23 | 2016-10-05 | ネクター セラピューティクス | ポリマー−スニチニブコンジュゲート |
UY33883A (es) | 2011-01-31 | 2012-08-31 | Novartis Ag | Novedosos derivados heterocíclicos |
US9353127B2 (en) | 2011-02-15 | 2016-05-31 | Immunogen, Inc. | Methods of preparation of conjugates |
JP5937112B2 (ja) | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited | 選択的fak阻害剤 |
WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
US8630703B2 (en) | 2011-03-09 | 2014-01-14 | Technion Research & Development Foundation Limited | Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination |
CN102115469A (zh) * | 2011-03-21 | 2011-07-06 | 浙江大学 | 吲哚啉-2-酮类衍生物的制备和用途 |
JP2014510122A (ja) | 2011-04-04 | 2014-04-24 | セルゾーム リミテッド | mTOR阻害剤としてのジヒドロピロロピリミジン誘導体 |
CN103945696B (zh) * | 2011-04-08 | 2016-06-29 | 贝达医药公司 | 新颖吲哚啉酮蛋白激酶抑制剂 |
CA2828946C (en) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
CN102898402B (zh) * | 2011-04-26 | 2016-01-20 | 北京大学 | 一种苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用 |
WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
KR20140047092A (ko) | 2011-07-28 | 2014-04-21 | 셀좀 리미티드 | Jak 억제제로서의 헤테로시클릴 피리미딘 유사체 |
WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
JP2014531449A (ja) | 2011-09-20 | 2014-11-27 | セルゾーム リミティッド | キナーゼ阻害剤としてのピラゾロ[4,3―c]ピリジン誘導体 |
US9175011B2 (en) | 2011-09-21 | 2015-11-03 | Cellzone Limited | Morpholino substituted urea or carbamate derivatives as MTOR inhibitors |
KR20140084130A (ko) | 2011-10-07 | 2014-07-04 | 셀좀 리미티드 | Mtor 억제제로서의 모르폴리노 치환된 바이사이클릭 피리미딘 우레아 또는 카르바메이트 유도체 |
CN102499917B (zh) | 2011-10-25 | 2014-12-17 | 澳门大学 | 吲哚酮类化合物在制备神经保护药物中的应用 |
AP2014007601A0 (en) | 2011-10-28 | 2014-04-30 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
CN103130774B (zh) * | 2011-11-22 | 2016-06-22 | 齐鲁制药有限公司 | 具有酪氨酸激酶抑制作用的化合物及其制备方法和应用 |
CN103127096B (zh) * | 2011-12-02 | 2015-11-25 | 杨子娇 | 吡咯基取代的吲哚类化合物在治疗青光眼病的应用 |
US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
KR20140114344A (ko) | 2011-12-23 | 2014-09-26 | 셀좀 리미티드 | 키나제 억제제로서의 피리미딘-2,4-디아민 유도체 |
CN102491932A (zh) * | 2011-12-26 | 2012-06-13 | 天津科技大学 | 一种3-吲哚啉酮类衍生物及其制备方法及其应用 |
US9206163B2 (en) | 2012-03-23 | 2015-12-08 | Laurus Labs Private Ltd. | Process for the preparation of sunitinib and its acid addition salts thereof |
EP2838538B1 (en) | 2012-04-20 | 2017-03-15 | Annji Pharmaceutical Co., Ltd. | Cyclopropanecarboxylate esters of purine analogues |
PL399027A1 (pl) | 2012-04-27 | 2013-10-28 | Instytut Farmaceutyczny | Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu |
CN102653521B (zh) * | 2012-04-27 | 2014-08-06 | 首都师范大学 | 吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途 |
WO2013164754A2 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Prostate-associated antigens and vaccine-based immunotherapy regimens |
US10213432B2 (en) | 2012-05-16 | 2019-02-26 | Novartis Ag | Dosage regimen for a PI-3 kinase inhibitor |
EP3505534A1 (en) | 2012-06-08 | 2019-07-03 | Sutro Biopharma, Inc. | Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use |
US9732161B2 (en) | 2012-06-26 | 2017-08-15 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
WO2014026243A1 (en) | 2012-08-17 | 2014-02-20 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
WO2014031566A1 (en) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
PL3584255T3 (pl) | 2012-08-31 | 2022-05-16 | Sutro Biopharma, Inc. | Modyfikowane aminokwasy zawierające grupę azydkową |
WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
ES2644758T3 (es) | 2012-10-16 | 2017-11-30 | Tolero Pharmaceuticals, Inc. | Moduladores de PKM2 y métodos para su uso |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
BR112015009004A8 (pt) | 2012-12-21 | 2021-07-20 | Eisai R&D Man Co Ltd | forma amorfa de derivado de quinolina e método de produção da mesma |
WO2014134486A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US9999680B2 (en) | 2013-02-28 | 2018-06-19 | Immunogen, Inc. | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents |
RU2015143526A (ru) * | 2013-03-13 | 2017-04-19 | Бостон Байомедикал, Инк. | Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака |
EP2968113B8 (en) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
ES2738493T3 (es) | 2013-03-14 | 2020-01-23 | Tolero Pharmaceuticals Inc | Inhibidores de JAK2 y ALK2 y métodos para su uso |
AR095443A1 (es) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
CN104119321B (zh) * | 2013-04-28 | 2017-09-08 | 齐鲁制药有限公司 | 二氢吲哚酮衍生物的二马来酸盐及其多晶型物 |
CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
FR3008411B1 (fr) * | 2013-07-12 | 2015-07-03 | Servier Lab | Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent |
PT3039424T (pt) | 2013-08-28 | 2020-09-03 | Crown Bioscience Inc Taicang | Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo |
US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
CA2838585A1 (en) | 2013-10-18 | 2015-04-18 | Hari Babu Matta | An ascorbic acid salt of sunitinib |
CA2838587A1 (en) | 2013-10-18 | 2015-04-18 | Hari Babu Matta | Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation |
MY182168A (en) | 2013-11-01 | 2021-01-18 | Pfizer | Vectors for expression of prostate-associated antigens |
CN105979947A (zh) | 2013-12-06 | 2016-09-28 | 诺华股份有限公司 | α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案 |
CN104829596B (zh) | 2014-02-10 | 2017-02-01 | 石家庄以岭药业股份有限公司 | 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途 |
CN103923014A (zh) * | 2014-05-05 | 2014-07-16 | 宁夏宝马药业有限公司 | 环肌酸制备方法 |
US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
EP3246046A4 (en) | 2015-01-13 | 2018-12-05 | Kyoto University | Agent for preventing and/or treating amyotrophic lateral sclerosis |
AU2016224583B2 (en) | 2015-02-25 | 2021-06-03 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
KR20170122809A (ko) | 2015-03-04 | 2017-11-06 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
WO2016172214A1 (en) | 2015-04-20 | 2016-10-27 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
WO2016184793A1 (en) | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma |
KR102608921B1 (ko) | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
KR20180034538A (ko) | 2015-08-03 | 2018-04-04 | 톨레로 파마수티컬스, 인크. | 암의 치료를 위한 병행 요법 |
MX2018003462A (es) | 2015-09-22 | 2018-09-06 | Graybug Vision Inc | Compuestos y composiciones para el tratamiento de trastornos oculares. |
GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
CN108472289A (zh) | 2015-11-02 | 2018-08-31 | 诺华股份有限公司 | 磷脂酰肌醇3-激酶抑制剂的给药方案 |
SG11201803663XA (en) | 2015-11-12 | 2018-05-30 | Graybug Vision Inc | Aggregating microparticles for therapy |
CA3011455A1 (en) | 2016-01-27 | 2017-08-03 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
WO2017139417A1 (en) | 2016-02-08 | 2017-08-17 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
EP3228630A1 (en) | 2016-04-07 | 2017-10-11 | IMBA-Institut für Molekulare Biotechnologie GmbH | Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer |
CN107459519A (zh) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
CA3035081A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
JP2019537585A (ja) | 2016-10-28 | 2019-12-26 | アイカーン スクール オブ メディスン アット マウント シナイ | Ezh2媒介性がんを治療するための組成物および方法 |
US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
MX2019006333A (es) | 2016-12-05 | 2019-09-26 | Apros Therapeutics Inc | Compuestos de pirimidina que contienen grupos ácidos. |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
WO2018106870A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
US10132797B2 (en) | 2016-12-19 | 2018-11-20 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
CN106916143B (zh) * | 2017-03-14 | 2019-09-27 | 哈尔滨医科大学 | 一种预防和治疗冠心病的药物及其应用 |
BR112019019452A2 (pt) | 2017-03-23 | 2020-04-14 | Graybug Vision Inc | composto, e, uso de um composto |
CN111201040A (zh) | 2017-05-10 | 2020-05-26 | 灰色视觉公司 | 用于医学疗法的缓释微粒及其悬浮液 |
US20200207859A1 (en) | 2017-07-26 | 2020-07-02 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
EP3684814A1 (en) | 2017-09-18 | 2020-07-29 | Sutro Biopharma, Inc. | Anti-folate receptor alpha antibody conjugates and their uses |
WO2019075367A1 (en) | 2017-10-13 | 2019-04-18 | Tolero Pharmaceuticals, Inc. | PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER |
NL2019801B1 (en) | 2017-10-25 | 2019-05-02 | Univ Leiden | Delivery vectors |
CN112154146A (zh) | 2018-03-06 | 2020-12-29 | 西奈山伊坎医学院 | 丝氨酸苏氨酸激酶(akt)降解/破坏化合物和使用方法 |
EP3539536A1 (en) | 2018-03-15 | 2019-09-18 | MH10 Spolka z ograniczona odpowiedzialnoscia | A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i |
EP3802519A1 (en) | 2018-06-04 | 2021-04-14 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7 |
GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
WO2020060944A1 (en) | 2018-09-17 | 2020-03-26 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
EP3890749A4 (en) | 2018-12-04 | 2022-08-03 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT |
JPWO2020130125A1 (ja) | 2018-12-21 | 2021-11-04 | 第一三共株式会社 | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
EP3941463A1 (en) | 2019-03-22 | 2022-01-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
EP3958845A1 (en) | 2019-04-25 | 2022-03-02 | Synthon B.V. | Pharmaceutical composition comprising amorphous sunitinib |
US20220362394A1 (en) | 2019-05-03 | 2022-11-17 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
WO2020227325A1 (en) | 2019-05-06 | 2020-11-12 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as degraders of hpk1 |
KR20220054840A (ko) | 2019-08-31 | 2022-05-03 | 이턴 바이오파마 (상하이) 코., 엘티디. | Fgfr 억제제용 피라졸류 유도체 및 이의 제조방법 |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4114852A1 (en) | 2020-03-03 | 2023-01-11 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
CN111233841A (zh) * | 2020-03-17 | 2020-06-05 | 湖北扬信医药科技有限公司 | 一种舒尼替尼有关物质及其制备方法和用途 |
WO2023278424A1 (en) * | 2021-06-28 | 2023-01-05 | The Regents Of The University Of California | Methods for treating and ameliorating t cell related diseases |
CN113717159A (zh) * | 2021-09-16 | 2021-11-30 | 中国药科大学 | 吲哚酮类化合物及其药物组合物、制备方法及用途 |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
US20240058465A1 (en) | 2022-06-30 | 2024-02-22 | Sutro Biopharma, Inc. | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates |
WO2024017372A1 (zh) * | 2022-07-22 | 2024-01-25 | 成都百裕制药股份有限公司 | 一种吲哚酮衍生物及其应用 |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL104796C (no) | 1957-08-19 | |||
DE878539C (de) | 1939-08-17 | 1953-06-05 | Hoechst Ag | Verfahren zur Herstellung von Methinfarbstoffen |
BE507136A (no) | 1950-11-18 | |||
BE553661A (no) | 1955-12-23 | |||
NL96047C (no) | 1956-06-08 | |||
NL251055A (no) | 1959-04-29 | |||
FR1398224A (fr) | 1964-05-06 | 1965-05-07 | Ici Ltd | Procédé de teinture de matières textiles de polyacrylonitrile |
US3308134A (en) | 1965-10-22 | 1967-03-07 | Mcneilab Inc | Spiro(indan-2, 3'-indoline)-1, 2'-diones |
US3551571A (en) | 1967-05-19 | 1970-12-29 | Endo Lab | Methods for reducing pain,reducing fever and alleviating inflammatory syndromes with heteroaromatic pyrrol-3-yl ketones |
US3564016A (en) | 1968-03-07 | 1971-02-16 | Endo Lab | Method of decarbonylation |
US4070366A (en) | 1968-06-12 | 1978-01-24 | Canadian Patents & Development Limited | Alkylation process |
FR1599772A (no) | 1968-09-17 | 1970-07-20 | ||
US3922163A (en) | 1970-01-30 | 1975-11-25 | Upjohn Co | Organic compounds and process |
US3715364A (en) | 1970-12-28 | 1973-02-06 | Merck & Co Inc | Nitroimidazole carboxamides |
DE2159361A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
DE2159363A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Antimikrobielle mittel |
DE2159360A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
DE2159362A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
GB1384599A (en) | 1972-05-04 | 1975-02-19 | Colgate Palmolive Co | Coloured detergent compositions |
US3880871A (en) | 1973-09-27 | 1975-04-29 | Squibb & Sons Inc | Isothiocyanophenyl substituted imidazoles |
US4002643A (en) | 1975-06-27 | 1977-01-11 | Mcneil Laboratories, Inc. | Preparation of β-acyl pyrroles |
US4002749A (en) | 1975-08-12 | 1977-01-11 | E. R. Squibb & Sons, Inc. | Substituted indolinones |
US4053613A (en) | 1975-09-17 | 1977-10-11 | E. R. Squibb & Sons, Inc. | 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones |
DE2855306A1 (de) | 1978-12-21 | 1980-07-10 | Boehringer Sohn Ingelheim | Mittel zur senkung der herzfrequenz |
GR73560B (no) | 1979-02-24 | 1984-03-15 | Pfizer | |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4343923A (en) | 1980-08-07 | 1982-08-10 | Armstrong World Industries, Inc. | Process for reducing the acid dye uptake of polyamide textile materials with N-acylimidazole compound |
CH646956A5 (de) | 1981-12-15 | 1984-12-28 | Ciba Geigy Ag | Imidazolide. |
EP0095285A1 (en) | 1982-05-21 | 1983-11-30 | Sumitomo Chemical Company, Limited | N-acylimidazoles, their production and use |
US4493642A (en) | 1982-12-27 | 1985-01-15 | Bogdon Glendon J | Orthodontic device and associated orthodontic method |
DE3310891A1 (de) | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
US4489089A (en) | 1983-04-06 | 1984-12-18 | American Cyanamid Company | Substituted N-[ω-(1H-imidazol-1-yl)alkyl]-amides |
DE3480392D1 (en) | 1983-04-29 | 1989-12-14 | Ciba Geigy Ag | Imidazolides and their use as curing agents for polyepoxides |
DE3415138A1 (de) | 1984-04-21 | 1985-10-31 | Basf Ag, 6700 Ludwigshafen | N-(azolylcarbamoyl)-hydroxylamine und diese enthaltende fungizide |
DE3426419A1 (de) | 1984-07-18 | 1986-01-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
US4560700A (en) | 1985-02-08 | 1985-12-24 | Merrell Dow Pharmaceuticals Inc. | Pyrrole-3-carboxylate cardiotonic agents |
JPH078851B2 (ja) | 1985-07-29 | 1995-02-01 | 鐘淵化学工業株式会社 | 3−フエニルチオメチルスチレン誘導体 |
US4966849A (en) | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
US4853404A (en) | 1986-10-13 | 1989-08-01 | Tanabe Seiyaku Co., Ltd. | Phenoxyacetic acid derivatives composition and use |
US5202341A (en) | 1987-03-11 | 1993-04-13 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Hydroxystyrene compounds having tyrosine kinase inhibiting activity |
DE3874257T2 (de) | 1987-03-11 | 1993-02-11 | Kanegafuchi Chemical Ind | Hydroxystyren-derivate. |
US5089516A (en) | 1987-03-11 | 1992-02-18 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity |
US5043348A (en) | 1987-04-24 | 1991-08-27 | Cassella Aktiengesellschaft | Pyrrolealdehydes, their preparation and their use |
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
DE3808071A1 (de) | 1988-03-11 | 1989-09-21 | Basf Ag | Verfahren zur herstellung von acylierten imidazolen |
US4868304A (en) | 1988-05-27 | 1989-09-19 | Iowa State University Research Foundation, Inc. | Synthesis of nitrogen heterocycles |
CA1339784C (en) | 1988-06-23 | 1998-03-31 | Shinya Inoue | Pyrrolecarboxylic acid derivatives |
JPH06104658B2 (ja) | 1988-06-23 | 1994-12-21 | 三菱化成株式会社 | ピロールカルボン酸誘導体 |
DE3824658A1 (de) | 1988-07-15 | 1990-01-18 | Schering Ag | N-hetaryl-imidazolderivate |
GB8816944D0 (en) | 1988-07-15 | 1988-08-17 | Sobio Lab | Compounds |
US5084280A (en) | 1988-12-15 | 1992-01-28 | Chapman Chemical Company | Wood preservation composition and method |
DE3902439A1 (de) | 1989-01-27 | 1990-08-02 | Basf Ag | Pflanzenschuetzende mittel auf basis von 1-aryl- bzw. 1-hetarylimidazolcarbonsaeureestern |
US5047554A (en) | 1989-04-18 | 1991-09-10 | Pfizer Inc. | 3-substituted-2-oxindole derivatives |
WO1991001306A1 (fr) | 1989-07-25 | 1991-02-07 | Taiho Pharmaceutical Company, Limited | Derive oxoindole |
US5258357A (en) | 1989-10-07 | 1993-11-02 | Basf Aktiengesellschaft | Carboxamides, their preparation and their use as herbicides |
CA2032421A1 (en) | 1989-12-20 | 1991-06-21 | Mitsubishi Chemical Corporation | Pyrrolealdehyde derivative |
GB9004483D0 (en) | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
CA2012634A1 (en) | 1990-03-20 | 1991-09-20 | Hassan Salari | Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases |
US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
IT1247509B (it) | 1991-04-19 | 1994-12-17 | Univ Cagliari | Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus |
ATE159009T1 (de) | 1991-05-10 | 1997-10-15 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9115160D0 (en) | 1991-07-12 | 1991-08-28 | Erba Carlo Spa | Methylen-oxindole derivatives and process for their preparation |
US5124347A (en) | 1991-07-31 | 1992-06-23 | Warner-Lambert Co. | 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents |
AU664392B2 (en) | 1991-10-18 | 1995-11-16 | Monsanto Technology Llc | Fungicides for the control of take-all disease of plants |
US5389661A (en) | 1991-12-05 | 1995-02-14 | Warner-Lambert Company | Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties |
US5322950A (en) | 1991-12-05 | 1994-06-21 | Warner-Lambert Company | Imidazole with angiotensin II antagonist properties |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
FR2689397A1 (fr) | 1992-04-01 | 1993-10-08 | Adir | Utilisation des dérivés de la 3-(3,5-Ditert-Butyl-4-Hydroxybenzylidenyl) Indoline-2-one pour l'obtention de médicaments. |
DE4211531A1 (de) | 1992-04-06 | 1993-10-07 | Cassella Ag | Verfahren zur Herstellung von Pyrrolderivaten |
FR2694004B1 (fr) | 1992-07-21 | 1994-08-26 | Adir | Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent. |
US5565324A (en) | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
JP3507124B2 (ja) | 1993-05-26 | 2004-03-15 | 塩野義製薬株式会社 | ベンジリデン誘導体の製造法 |
DE59402281D1 (de) | 1993-06-28 | 1997-05-07 | Bayer Ag | Massefärben von Kunststoffen |
US5332736A (en) | 1993-11-01 | 1994-07-26 | Ortho Pharmaceutical Corporation | Anti-convulsant aroyl aminoacylpyrroles |
US5610173A (en) | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
GB9507298D0 (en) | 1995-04-07 | 1995-05-31 | Pharmacia Spa | Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors |
US5786488A (en) | 1996-11-13 | 1998-07-28 | Sugen, Inc. | Synthetic methods for the preparation of indolyquinones |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
JP3246712B2 (ja) | 1995-11-15 | 2002-01-15 | 株式会社トクヤマ | エテニルアミド化合物の製造方法 |
EP0788890A1 (en) | 1996-02-06 | 1997-08-13 | Agfa-Gevaert N.V. | Dyes and dye-donor elements for thermal dye transfer recording |
CA2206201A1 (en) | 1996-05-29 | 1997-11-29 | Yoshiaki Isobe | Pyrazole derivatives and their pharmaceutical use |
KR100482268B1 (ko) | 1996-08-01 | 2005-04-14 | 메르클레 게엠베하 | 세포질 포스포리파제 a2의 저해제로서의 아실피롤디카르복실산 |
JP2002511852A (ja) * | 1997-05-07 | 2002-04-16 | スージェン・インコーポレーテッド | 蛋白質キナーゼ活性の調節剤としての2−インドリノン誘導体 |
US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
TR200003514T2 (tr) * | 1998-05-29 | 2002-05-21 | Sugen Inc. | Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri |
US6462072B1 (en) | 1998-09-21 | 2002-10-08 | Gpi Nil Holdings, Inc. | Cyclic ester or amide derivatives |
CN1149983C (zh) | 1998-12-14 | 2004-05-19 | 赛勒吉药物股份有限公司 | 用于治疗肛门直肠病的组合物和方法 |
JP2002532492A (ja) * | 1998-12-17 | 2002-10-02 | エフ.ホフマン−ラ ロシュ アーゲー | サイクリン−依存性キナーゼ、特にcdk2のインヒビターとしての4−アルケニル(及びアルキニル)オキシドール |
US6284894B1 (en) | 1998-12-18 | 2001-09-04 | Nycomed Imaging As | Preparation of allylic aromatic compounds |
AU760964B2 (en) * | 1998-12-31 | 2003-05-22 | Sugen, Inc. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy |
ATE514676T1 (de) * | 1999-11-24 | 2011-07-15 | Sugen Inc | Ionisierbare indolinon derivate und deren verwendung als ptk liganden |
MXPA02006263A (es) * | 1999-12-22 | 2004-02-26 | Sugen Inc | Metodos de modulacion de la funcion de la cinasa de tirosina c-kit de la proteina con compuestos de indolinona. |
ME00415B (me) * | 2000-02-15 | 2011-10-10 | Pharmacia & Upjohn Co Llc | Pirol supstituisani 2-indol protein kinazni inhibitori |
TWI270545B (en) | 2000-05-24 | 2007-01-11 | Sugen Inc | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
WO2002002551A1 (en) * | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
JP2004518669A (ja) * | 2000-12-20 | 2004-06-24 | スージェン・インコーポレーテッド | 4−アリール置換インドリノン |
-
2001
- 2001-02-15 ME MEP-2008-530A patent/ME00415B/me unknown
- 2001-02-15 CA CA002399358A patent/CA2399358C/en not_active Expired - Lifetime
- 2001-02-15 AU AU3977001A patent/AU3977001A/xx active Pending
- 2001-02-15 MX MXPA02008021A patent/MXPA02008021A/es active IP Right Grant
- 2001-02-15 AT AT01914376T patent/ATE369359T1/de active
- 2001-02-15 CN CNB018072690A patent/CN1329390C/zh not_active Expired - Lifetime
- 2001-02-15 NZ NZ520640A patent/NZ520640A/en not_active IP Right Cessation
- 2001-02-15 AU AU2001239770A patent/AU2001239770B2/en not_active Expired
- 2001-02-15 BR BRPI0117360A patent/BRPI0117360B8/pt not_active IP Right Cessation
- 2001-02-15 JP JP2001560198A patent/JP3663382B2/ja not_active Expired - Lifetime
- 2001-02-15 RS YUP-614/02A patent/RS50444B/sr unknown
- 2001-02-15 DE DE60129794T patent/DE60129794T2/de not_active Expired - Lifetime
- 2001-02-15 SI SI200130778T patent/SI1255752T1/sl unknown
- 2001-02-15 PT PT01914376T patent/PT1255752E/pt unknown
- 2001-02-15 IL IL15112701A patent/IL151127A0/xx active Protection Beyond IP Right Term
- 2001-02-15 DE DE122010000004C patent/DE122010000004I1/de active Pending
- 2001-02-15 UA UA2002097427A patent/UA73976C2/uk unknown
- 2001-02-15 EP EP01914376A patent/EP1255752B1/en not_active Expired - Lifetime
- 2001-02-15 PE PE2001000172A patent/PE20011083A1/es active IP Right Grant
- 2001-02-15 HU HU0204433A patent/HU228979B1/hu active Protection Beyond IP Right Term
- 2001-02-15 ES ES01914376T patent/ES2290117T3/es not_active Expired - Lifetime
- 2001-02-15 DK DK01914376T patent/DK1255752T3/da active
- 2001-02-15 PL PL361209A patent/PL211834B1/pl unknown
- 2001-02-15 US US09/783,264 patent/US6573293B2/en not_active Expired - Lifetime
- 2001-02-15 MY MYPI20010696A patent/MY130363A/en unknown
- 2001-02-15 KR KR1020027010706A patent/KR100713960B1/ko active IP Right Grant
- 2001-02-15 SK SK1326-2002A patent/SK287142B6/sk not_active IP Right Cessation
- 2001-02-15 DE DE122008000002C patent/DE122008000002I1/de active Pending
- 2001-02-15 CZ CZ20023081A patent/CZ303705B6/cs unknown
- 2001-02-15 EA EA200200862A patent/EA005996B1/ru not_active IP Right Cessation
- 2001-02-15 AR ARP010100703A patent/AR034118A1/es active IP Right Grant
- 2001-02-15 CO CO01012068A patent/CO5280092A1/es not_active Application Discontinuation
- 2001-02-15 WO PCT/US2001/004813 patent/WO2001060814A2/en active Application Filing
- 2001-02-15 BR BR0108394-5 patent/BRPI0108394B8/pt not_active IP Right Cessation
- 2001-07-04 TW TW090103496A patent/TWI306860B/zh not_active IP Right Cessation
-
2002
- 2002-08-13 IS IS6501A patent/IS2491B/is unknown
- 2002-08-13 NO NO20023831A patent/NO325532B1/no not_active IP Right Cessation
- 2002-09-10 BG BG107078A patent/BG65764B1/bg unknown
- 2002-09-13 HR HR20020751A patent/HRP20020751B1/xx not_active IP Right Cessation
-
2003
- 2003-04-14 US US10/412,690 patent/US20040063773A1/en not_active Abandoned
- 2003-05-12 HK HK03103304A patent/HK1051188A1/xx not_active IP Right Cessation
-
2005
- 2005-01-04 US US11/028,477 patent/US7125905B2/en not_active Expired - Lifetime
-
2006
- 2006-09-06 US US11/517,529 patent/US7572924B2/en not_active Expired - Lifetime
-
2007
- 2007-09-13 CY CY20071101186T patent/CY1108032T1/el unknown
-
2008
- 2008-01-08 NL NL300332C patent/NL300332I2/nl unknown
- 2008-01-09 LU LU91407C patent/LU91407I2/fr unknown
- 2008-01-15 FR FR08C0002C patent/FR08C0002I2/fr active Active
- 2008-02-04 LT LTPA2008002C patent/LTC1255752I2/lt unknown
- 2008-02-08 CY CY200800004C patent/CY2008004I2/el unknown
- 2008-12-08 NO NO2008019C patent/NO2008019I2/no unknown
-
2009
- 2009-12-29 NL NL300430C patent/NL300430I2/nl unknown
-
2010
- 2010-02-09 NO NO2010002C patent/NO2010002I2/no unknown
- 2010-02-11 BE BE2010C009C patent/BE2010C009I2/fr unknown
- 2010-03-03 LU LU91657C patent/LU91657I2/fr unknown
- 2010-03-09 CY CY2010004C patent/CY2010004I2/el unknown
-
2012
- 2012-01-09 CR CR20120009A patent/CR20120009A/es unknown
- 2012-01-09 CR CR20120007A patent/CR20120007A/es unknown
-
2019
- 2019-02-05 NO NO2019005C patent/NO2019005I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20023831L (no) | Pyrrol substituert 2-indolinonproteinkinaseinhibitorer | |
MY126235A (en) | 3-(4-amidopyrrol-2-ylmethylidene) -2- indolinone derivatives as protein kinase inhibitors. | |
MY139689A (en) | Imidazotriazines as protein kinase inhibitors | |
NO20084496L (no) | Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer | |
NO20065727L (no) | Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter | |
MY128449A (en) | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | |
NO20076659L (no) | Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer | |
NO20030381L (no) | Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser | |
NO20082508L (no) | Aminopyrimidiner anvendelige som kinaseinhibitorer | |
SG132683A1 (en) | Imidazopyrazine tyrosine kinase inhibitors | |
TW200407311A (en) | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | |
NO20062188L (no) | Pyrazolderivater som inhibitorer av reseptor tyrosin kinaser | |
MXPA02005844A (es) | Inhibidores de cinasas de proteina. | |
NO20061194L (no) | Mitotiske kinesininbibitorer | |
NO20080162L (no) | Tienopyrimidin og tienopyrimidinderivater som FLT-3 kinaseinhibitorer | |
BR0212435A (pt) | Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase | |
NO20080417L (no) | Benzosykloheptapyridiner som inhibitorer av reseptortyrosinkinasen MET | |
MXPA05009151A (es) | Inhibidores de cinasa heterociclica. | |
MXPA02010759A (es) | Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: BRYN AARFLOT AS POSTBOKS 449 SENTRUM OSLO, 0104 NO |
|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: PALLADIA - TOCERANIB; NAT. REG. NO/DATE: EU/2/09/100/001-3/NO 20091029; FIRST REG. NO/DATE: EU/2/09/100/001-003 20090923 Spc suppl protection certif: 2010002 Filing date: 20100209 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: PALLADIA - TOCERANIB; NAT. REG. NO/DATE: EU/2/09/100/001-3/NO 20091029; FIRST REG. NO/DATE: EU/2/09/100/001-003 20090923 Spc suppl protection certif: 2010002 Filing date: 20100209 Extension date: 20240923 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: SUTENT - SUNITINIB; NAT. REG. NO/DATE: EU106347001-003 20060727; FIRST REG. NO/DATE: EU , EU106347001-003 20060719 Spc suppl protection certif: 2008019 Filing date: 20081208 Extension date: 20210719 |
|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: N-[2-(DIETYLAMINO)ETYL]-5-[(Z)-(5-FLUORO-2-OKSO-1,2-DIHYDRO-3H-INDOL-3-YLIDEN)METYL]-2,4-DIMETYL-1H-PYRROL-3-KARBOKSAMID (SUNITINIB), SAMT FARMASOEYTISK AKSEPTABLE SALTER; NAT. REG. NO/DATE: NO , 2008019 20081208 Spc suppl protection certif: 2019005 Filing date: 20190205 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: N-(2-(DIETYLAMINO)ETYL)-5-((Z)-; REG. NO/DATE: 2008019 20081208 Spc suppl protection certif: 2019005 Filing date: 20190205 Extension date: 20220124 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: N-(2-(DIETYLAMINO)ETYL)-5-((Z)-; REG. NO/DATE: 2008019 20081208 Spc suppl protection certif: 2019005 Filing date: 20190205 Extension date: 20220124 |
|
MK1K | Patent expired | ||
SPCX | Expiry of an spc |
Spc suppl protection certif: 2019005 |
|
SPCX | Expiry of an spc |
Spc suppl protection certif: 2008019 |